In mice, blocking CB1 receptors increased anxiety while boosting anandamide through FAAH inhibition reduced it, suggesting indirect endocannabinoid enhancement may be more promising for anxiety treatment.
Neuroscience researchers and pharmaceutical developers targeting the endocannabinoid system for anxiety.
FAAH inhibitor URB 597 reduced anxiety at 0.3 mg/kg
What the researchers found
CB1 antagonist AM 251 was anxiogenic. Mixed agonist WIN55,212-2 (1 mg/kg) was anxiolytic. Both CB2 agonist and antagonist increased anxiety. FAAH inhibitor URB 597 (0.3 mg/kg) was anxiolytic. MAGL inhibitor JZL 184 had no effect.
Why it matters
This systematic comparison identifies FAAH inhibition as the most promising endocannabinoid approach for anxiety, while revealing that CB2 manipulation paradoxically increases anxiety.
The numbers in context
URB 597 anxiolytic at 0.3 mg/kg; AM 251 anxiogenic at 0.25-3 mg/kg; WIN55,212-2 anxiolytic at 1 mg/kg; JZL 184 no effect at 2-40 mg/kg.
How the study worked
Acute drug administration in mice assessed in the elevated plus maze. Multiple receptor ligands and enzyme inhibitors tested with dose-response curves.
What this study cannot tell us
Animal model. Acute dosing only. Single mouse strain. EPM captures one dimension of anxiety.
How to read the evidence
Systematic compound comparison, but single animal model with acute dosing limits translation.
When this study was published
2025 study comparing endocannabinoid manipulation strategies for anxiety.
The bigger picture
Boosting anandamide through enzyme inhibition appears more reliable than direct receptor activation for reducing anxiety.
Questions still open
- Why does CB2 manipulation (both agonism and antagonism) increase anxiety?
- Would chronic FAAH inhibition maintain effects?
Common questions
Can the endocannabinoid system treat anxiety?
Why did both CB2 agonists and antagonists increase anxiety?
Read the original research
The Effects of Indirect and Direct Modulation of Endocannabinoid System Function on Anxiety-Related Behavior in Mice Assessed in the Elevated Plus Maze Test.
Molecules (Basel, Switzerland), 30(4)
Citation
Kruk-Slomka, Marta; Dzik, Agnieszka; Biala, Grazyna. (2025). The Effects of Indirect and Direct Modulation of Endocannabinoid System Function on Anxiety-Related Behavior in Mice Assessed in the Elevated Plus Maze Test.. Molecules (Basel, Switzerland), 30(4). https://doi.org/10.3390/molecules30040867
Explore the wider topic
- Weed Withdrawal Anxiety in Public: When Leaving the House Feels Impossible
- The DARE Response to Anxiety for Cannabis Withdrawal
- The Cannabis Withdrawal Anxiety Toolkit: Quick Techniques That Work
- Why Anxiety Gets Worse Before It Gets Better After Quitting Weed
- Breathing Exercises for Weed Withdrawal Anxiety
- Cannabis-Induced Anxiety: When Weed Stops Being Fun
- Does Weed Help or Hurt Anxiety? What Research Actually Shows
- Grounding Techniques for Cannabis Withdrawal: A Practical Toolkit
- Quitting Weed with Health Anxiety: Why Every Symptom Feels Like a Crisis
- How to Manage Anxiety Without Weed: 15 Evidence-Based Alternatives
- Quitting Weed with Anxiety Disorder: A Careful Approach
- Quitting Weed When You're on Anxiety Medication: What to Know
- Self-Medicating Anxiety with Weed: Why It Works Until It Doesn't
- Do I Need Therapy to Quit Weed? When Professional Help Makes Sense
- Weed and Anxiety: The Paradox That Traps People
- The Biphasic Effect: Low-Dose Calms, High-Dose Panics
- Weed and Generalized Anxiety Disorder (GAD): Why It Backfires
- Weed and Panic Attacks: The Connection Nobody Talks About
- Weed and Paranoia: When Cannabis Turns Your Mind Against You
- Weed and Social Anxiety: Why It Feels Like the Only Thing That Helps
- Why Weed Stopped Working for Your Anxiety
- Weed Withdrawal Anxiety: Understanding the Panic and How to Cope
- Weed Withdrawal Panic Attacks at Night: Why They Happen and How to Get Through Them
- Going Back to Work During Weed Withdrawal: Managing Anxiety and Staying Functional
- Withdrawal Anxiety vs Pre-Existing Anxiety: How to Tell the Difference